对于骨折风险的PTH1受体激动剂:系统性审查和网络元分析
Charlotte Beaudart1,2, Nicola Veronese3,4, Jonathan Douxfils5,6,7
1World Health Organization (WHO) Collaborating Center for Epidemiology of Musculoskeletal Health and Ageing, University of Liège, Liège, Belgium. charlotte.beaudart@unamur.be.
概括
甲状腺激素 (PTH) 的类似物,特里巴拉提德和阿巴洛巴拉提德,有效降低骨质疏松症患者的骨折风险. 与teriparatide相比,阿巴洛帕拉提德对非脊椎和关节骨折的疗效更大,两种药物都显示出有利的安全性.
科学领域:
- 内分泌学和骨代谢 骨质代谢
- 对骨质疏松症的药理干预措施
背景情况:
- 骨质疏松症的特点是骨矿物质密度下降和骨结构恶化,骨折风险增加,特别是在老年人中.
- 随机对照试验 (RCT) 证实了副甲状腺激素1型 (PTH1) 受体激素激剂,特里帕拉蒂德和阿巴洛帕拉蒂德在减少骨折方面的有效性,但现实世界的证据 (RWE) 是有限的.
研究的目的:
- 系统地审查和比较teriparatide和abaloparatide的抗骨折疗效,并将其与其他骨质疏松症治疗方法相比较.
- 用随机对照试验 (RCT) 和现实世界的证据 (RWE) 来评估疗效.
- 评估这些药物的安全性.
主要方法:
- 在Medline,Embase和Cochrane数据库中进行系统的文献搜索,直到2024年5月为RCT和RWE研究.
- 纳入标准侧重于报告骨折减少 (脊椎,非脊椎,部或所有) 作为主要终点的研究.
- 网络元分析 (NMA),包括对联元分析和贝叶斯元分析;使用MedDRA不良事件分类进行安全性评估.
主要成果:
- 与安慰剂相比, teriparatide 和 abaloparatide 均显著减少了脊椎和非脊椎骨折.
- 阿巴洛帕拉提德在非脊椎骨折 (OR:0.87) 和部骨折 (OR:0.81) 中表现出比特里巴提德更高的疗效.
- 在NMA中,两种PTH1类型的药物在脊椎骨折中都超过了安慰剂,拉洛西芬和;teriparatide也超过了denosumab和risedronate. 阿巴洛帕拉提德在非脊椎骨折方面优越,而特里帕拉提德仅在阿伦德罗纳特或安慰剂上表现出优越性.
结论:
- PTH1受体激动剂有效降低骨折风险,阿巴洛帕拉提德与特里帕拉提德相比,在非脊椎和关节骨折方面显示出更大的益处.
- 这两种药物都具有与其他骨质疏松症治疗相似的安全性,而心血管风险没有增加.
- 特里巴拉提德和阿巴洛巴拉提德是治疗骨质疏松症的有价值的治疗方案,特别是在高风险患者群体中.
关键词:
阿巴洛帕拉蒂德 (Abaloparatide) 是一种类型.骨折 骨折 骨折 骨折 在马子 马子 马子网络元分析 网络元分析骨质疏松症是一种骨质疏松症.作为PTH-1受体的激动剂.随机对照试验是随机对照试验.现实世界的证据研究研究.安全的安全的安全的安全的安全.泰里巴拉提德是什么更多相关视频
04:19Minimally Invasive Treatment for Thoracolumbar Burst Fracture Using Sagittal Alignment Screws and A Trauma Reduction Device
Published on: November 8, 2024
385
![Quantitative [18F]-Naf-PET-MRI Analysis for the Evaluation of Dynamic Bone Turnover in a Patient with Facetogenic Low Back Pain](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F58491.jpg&w=3840&q=50)
06:31Quantitative [18F]-Naf-PET-MRI Analysis for the Evaluation of Dynamic Bone Turnover in a Patient with Facetogenic Low Back Pain
Published on: August 8, 2019
7.3K
相关概念视频
01:27Fractures: Bone Repair
3.0K
Treatment for a fracture is based on the type of break, the bone affected, and the patient's age.
Minor fractures with no bone displacement are treated by immobilizing the fractured bone using a cast or splint. However, in the case of fractures with displaced bones, the broken bones are repositioned before immobilization to ensure successful healing without deformation and loss of function. The realignment of fractured bone ends is performed through a process called reduction. If the...
Minor fractures with no bone displacement are treated by immobilizing the fractured bone using a cast or splint. However, in the case of fractures with displaced bones, the broken bones are repositioned before immobilization to ensure successful healing without deformation and loss of function. The realignment of fractured bone ends is performed through a process called reduction. If the...
3.0K
01:31Osteoclasts in Bone Remodeling
2.8K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
2.8K
01:29Bone Disorders
3.4K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
3.4K
01:17Hormones and Bone Tissue
2.6K
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
2.6K
01:40Bone Remodeling
38.2K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
38.2K
01:21Drug Distribution: Tissue Binding
2.6K
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
For...
2.6K